<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101535383</journal-id>
<journal-id journal-id-type="pubmed-jr-id">38547</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Top Behav Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr Top Behav Neurosci</journal-id>
<journal-title-group>
<journal-title>Current topics in behavioral neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1866-3370</issn>
<issn pub-type="epub">1866-3389</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28812273</article-id>
<article-id pub-id-type="pmc">5815942</article-id>
<article-id pub-id-type="doi">10.1007/7854_2017_29</article-id>
<article-id pub-id-type="manuscript">NIHMS938444</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Precision Medicine Approach to Oxytocin Trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Andari</surname>
<given-names>Elissar</given-names>
</name>
<aff id="A1">Division of Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, Center for Translational Social Neuroscience, Emory University, Atlanta, GA, USA</aff>
<!--<email>eandari@gmail.com</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hurlemann</surname>
<given-names>Rene</given-names>
</name>
<aff id="A2">Department of Psychiatry, Medical Psychology Division, NEMO (Neuromodulation of Emotion) Research Group, University of Bonn, Bonn, Germany</aff>
<!--<email>renehurlemann@icloud.com</email>-->
</contrib>
<contrib contrib-type="author">
<name>
<surname>Young</surname>
<given-names>Larry J.</given-names>
</name>
<aff id="A3">Department of Psychiatry, Center for Translational Social Neuroscience, Division of Behavioral Neuroscience and Psychiatric Disorders, Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA</aff>
<!--<email>lyoun03@emory.edu</email>-->
</contrib>
</contrib-group>
<pub-date pub-type="nihms-submitted">
<day>1</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<fpage>559</fpage>
<lpage>590</lpage>
<!--elocation-id from pubmed: 10.1007/7854_2017_29-->
<abstract>
<p id="P1">In this chapter, we introduce a new area of social pharmacology that encompasses the study of the role of neuromodulators in modulating a wide range of social behaviors and brain function, with the interplay of genetic and epigenetic factors. There are increasing evidences for the role of the neuropeptide oxytocin in modulating a wide range of social behaviors, in reducing anxiety, and in impacting the social brain network. Oxytocin also promotes social functions in patients with neuropsychiatric disorders, such as autism and reduces anxiety and fear in anxiety disorders. In this chapter, we will emphasize the importance of integrating basic research and clinical human research in determining optimal strategies for drug discoveries for social dysfunctions and anxiety disorders. We will highlight the significance of adopting a precision medicine approach to optimize targeted treatments with oxytocin in neuropsychiatry. Oxytocin effects on social behavior and brain function can vary from one individual to another based on external factors, such as heterogeneity in autism phenotype, childhood experiences, personality, attachment style, and oxytocin receptor polymorphisms. Hence, targeted therapies for subgroups of patients can help alleviating some of the core symptoms and lead to a better future for these patients and their families.</p>
</abstract>
<kwd-group>
<kwd>Anxiety disorders</kwd>
<kwd>Autism</kwd>
<kwd>Oxytocin</kwd>
<kwd>Precision medicine</kwd>
<kwd>Social salience network</kwd>
<kwd>Targeted therapies</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>